Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in ART-Naïve Pregnant Women

NCT07616739 is registered in ClinicalTrials.gov with Fundación Huésped as lead sponsor.

NCT NCT07616739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07616739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in ART-Naïve Pregnant Women
Lead sponsor
Fundación Huésped
Phase
Phase 4
Overall status
Recruiting
Start date
September 10, 2026
Completion date
October 15, 2028
Enrollment
210 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection